Last reviewed · How we verify
Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently FDA-approved. Also known as: TRIMOVAX™, AVAXIM™.
At a glance
| Generic name | Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine |
|---|---|
| Also known as | TRIMOVAX™, AVAXIM™ |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants (PHASE4)
- Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers (PHASE3)
- Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life (PHASE3)
- Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age (PHASE3)
- Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) (PHASE3)
- Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine CI brief — competitive landscape report
- Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine updates RSS · CI watch RSS
- Sanofi Pasteur, a Sanofi Company portfolio CI
Frequently asked questions about Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine
What is Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine?
Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine is a Biologic drug developed by Sanofi Pasteur, a Sanofi Company.
Who makes Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine?
Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine is developed and marketed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).
Is Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine also known as anything else?
Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine is also known as TRIMOVAX™, AVAXIM™.
What development phase is Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine in?
Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine is FDA-approved (marketed).
Related
- Manufacturer: Sanofi Pasteur, a Sanofi Company — full pipeline
- Also known as: TRIMOVAX™, AVAXIM™
- Compare: Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine vs similar drugs
- Pricing: Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine cost, discount & access